Exploring Metformin's Therapeutic Potential for Alzheimer's Disease: An In-Silico Perspective Using Well-Tempered...

Area of Science:

• Neuroscience
• Computational Chemistry
• Pharmacology

Background:

• Alzheimer's disease (AD) is linked to insulin resistance, with metformin, an antidiabetic drug, showing potential as an AD therapeutic.
• Metformin is currently in phase 3 clinical trials for AD treatment, offering hope for millions affected worldwide.
• The exact molecular mechanisms of metformin's therapeutic effects in AD are not well understood.

Purpose of the Study:

• To investigate the molecular mechanisms of metformin's interaction with acetylcholinesterase (AChE), a novel target for Alzheimer's disease.
• To explore the dynamics and binding affinity of metformin to AChE using computational methods.

Main Methods:

• Classical molecular dynamics (MD) simulations were employed to study the behavior of metformin and AChE.
• Enhanced sampling technique, funnel metadynamics (FM), was utilized to explore the conformational landscape and binding.
• Molecular mechanics Poisson-Boltzmann surface area (MMPBSA) was used to estimate binding energies.

Main Results:

• Metformin induces significant configurational changes in AChE, leading to weak and nonspecific binding.
• Metformin alters the conformational landscape of AChE, creating metastable states and less rigid binding patterns.
• Binding energies calculated by MMPBSA and FM suggest moderate inhibitory potency of metformin against AChE.

Conclusions:

• Metformin exhibits moderate inhibitory effects on AChE, providing molecular-level insights into its potential therapeutic role in AD.
• The study highlights the dynamic structural changes induced by metformin in AChE, supporting its translational potential for AD repurposing.
• Further research into metformin's interaction with AChE could pave the way for novel Alzheimer's disease management strategies.